Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02308228 · ClinicalTrials.gov registry record · Early Phase 1
Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)
A Early Phase 1 study, sponsored by Philip Kern.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 109
- Enrollment target
NCT02308228: Completed Early Phase 1 study, sponsored by Philip Kern.
NCT02308228 is a Early Phase 1 study that has completed, run by Philip Kern. The registered enrollment target is 109 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (106% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02308228, a Early Phase 1 study, has completed, sponsored by Philip Kern.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 109 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a commonly prescribed drug, metformin, can enhance the benefits seen during resistance exercise such as increased muscle mass and strength.
Primary Outcome
The ability of metformin to improve the hypertrophic response to resistance training will be determined. Muscle biopsies of the vastus lateralis will be used to quantify myofiber cross-sectional area. The percent change in type 2 myofiber size between week 16 and week 0 was used.
Interventions
- DRUG Metformin
- BEHAVIORAL Progressive Resistance Training
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2015-01-14 |
| Est. Completion | 2018-06-28 |
| Phase | Early Phase 1 |
What the finished NCT02308228 record still lists
NCT02308228 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (106% higher).
The record links to 0 conditions, and to 2 interventions - of which Metformin is the first listed.
NCT02308228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02308228 about?
NCT02308228 is a clinical study titled "Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)". The purpose of this study is to determine whether a commonly prescribed drug, metformin, can enhance the benefits seen during resistance exercise such as increased muscle mass and strength.
What is the current status of trial NCT02308228?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 109 participants. The study started on 2015-01-14. Estimated completion is 2018-06-28.
What interventions are being tested in trial NCT02308228?
The interventions under investigation include: Metformin (DRUG), Progressive Resistance Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT02308228?
This trial is sponsored by Philip Kern, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02308228's enrollment target sits among peer trials
109 169th of 2000 higher than 1,832 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI